Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met

EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met   Suzhou, December 1, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced […]

Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use

EQS Newswire / 24/11/2022 / 09:48 UTC+8 Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use     Suzhou, November 24, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase […]

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

EQS Newswire / 27/10/2022 / 17:58 UTC+8 Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US   Suzhou, October 27, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company […]

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EQS Newswire / 08/09/2022 / 23:42 EST/EDT Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose […]

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

SYDNEY, Sep 2, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled “Evolution of Clinical Trials in the Asia Pacific Region”. The report was prepared by GlobalData and confirms that “the Asia-Pacific (APAC) region was the largest contributor […]

Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented

EQS Newswire / 30/08/2022 / 11:13 UTC+8 Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented   Suzhou, August 29, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma” or “the Company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results […]

Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June […]

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

HONG KONG, Aug 15, 2022 – (ACN Newswire via SEAPRWire.com) – On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. R&G Pharmastudies publicly issued 15,000,000 shares at a price of RMB78.88 per share, and the […]

Virios Therapeutics: The ‘Virus Hypothesis’ That Stands to Change the Lives of 10M Americans

NEW YORK, NY, Aug 9, 2022 – (ACN Newswire via SEAPRWire.com) – PCG Digital — Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (Nasdaq:VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues […]

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

LAUSANNE, Switzerland, Jun 29, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, today announced that the first patient has been enrolled in its Phase 3 OPTIMIZE (Once-daily Post ocular surgery Treatment for InflaMmation and paIn to […]

Novotech Receives “Best Biologics CRO Award 2022” at Korea Bioprocessing Excellence Awards 2022

SEOUL, S.KOREA, Jun 29, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, […]

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

HONG KONG, Jun 15, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject […]

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan

TOKYO, May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin (development code: E0302) for amyotrophic lateral sclerosis (ALS) in Japan, based on a favorable clinical results of the JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for […]

Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 – (ACN Newswire via SEAPRWire.com) – Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021. Highlights— The group’s turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million; — Sales coverage increased to around 10,500 […]

Fujitsu Leverages World’s Fastest Supercomputer and AI Tech in Joint Field Trial for Safe and Efficient Tsunami Evacuations in Kawasaki City

TOKYO, Mar 3, 2022 – (JCN Newswire via SEAPRWire.com) – The International Research Institute of Disaster Science (IRIDeS) at Tohoku University, the Earthquake Research Institute at the University of Tokyo, Fujitsu, and the City of Kawasaki(1) today announced plans to conduct a field trial of AI that is constructed on the world’s fastest supercomputer, Japan’s […]

Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report

SYDNEY, Feb 9, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the 2021 CenterWatch Global Site Relationship Benchmark Survey. Report available here. https://novotech-cro.com/news/novotech-recognized-top-10-cro-centerwatch-site-relationship-benchmarking-report CenterWatch, established in 1994, is a global benchmarking authority for the clinical trials sector. The benchmarking […]

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 30 November 2021, SM03 (Suciraslimab) Phase III […]